Canada’s health regulator has approved Novo Nordisk’s weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.
Trending
- 3 Americans held for years in China have been released, the White House says
- The Israel-Hezbollah ceasefire quiets one front but Gaza sees no end to war
- $100 million up for grabs after no Lotto Max grand prize winner Tuesday
- Elon Musk publicized the names of U.S. government employees he wants to cut. It’s terrifying federal workers
- Two companies drop McGregor after civil jury ruled he must pay US$250K to woman who says he raped her
- Canada approves Novo Nordisk’s obesity drug to reduce risk of non-fatal heart attack
- Israel-Hezbollah ceasefire appears to hold as Lebanese begin streaming south to their homes
- The son of Norway’s crown princess to be released from custody in rape allegations
Canada approves Novo Nordisk’s obesity drug to reduce risk of non-fatal heart attack
By
Add A Comment